Exact Sciences FY2026 EPS Forecast Lifted by Leerink Partnrs

Exact Sciences Co. (NASDAQ:EXAS) – Investment analysts at Leerink Partnrs raised their FY2026 earnings estimates for Exact Sciences in a research note issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $0.81 per share for the year, up from their previous estimate of $0.80. The consensus estimate for Exact Sciences’ current full-year earnings is ($1.10) per share.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The firm had revenue of $708.66 million for the quarter, compared to analysts’ expectations of $716.80 million. The business’s quarterly revenue was up 12.8% on a year-over-year basis.

Several other research analysts have also recently issued reports on the stock. Canaccord Genuity Group cut their target price on shares of Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. The Goldman Sachs Group cut their price target on shares of Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Craig Hallum lowered their price objective on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. TD Cowen raised their target price on Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Finally, Stifel Nicolaus lowered their price target on Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $72.94.

Exact Sciences Price Performance

EXAS stock opened at $54.79 on Wednesday. The firm’s fifty day moving average is $57.32 and its 200 day moving average is $59.35. Exact Sciences has a 52 week low of $40.62 and a 52 week high of $79.62. The firm has a market cap of $10.14 billion, a P/E ratio of -46.83 and a beta of 1.24. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12.

Hedge Funds Weigh In On Exact Sciences

A number of hedge funds have recently bought and sold shares of the company. WCM Investment Management LLC raised its holdings in Exact Sciences by 1,153.2% in the third quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock worth $12,388,000 after buying an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. increased its position in shares of Exact Sciences by 67.5% during the third quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock valued at $1,994,000 after acquiring an additional 11,800 shares in the last quarter. Zacks Investment Management purchased a new position in Exact Sciences in the 3rd quarter worth approximately $2,083,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Exact Sciences by 59.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock valued at $22,868,000 after acquiring an additional 125,192 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Exact Sciences by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock valued at $88,017,000 after purchasing an additional 45,015 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Insider Activity at Exact Sciences

In related news, CEO Kevin T. Conroy bought 19,500 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were purchased at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the purchase, the chief executive officer now owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. The trade was a 1.85 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.36% of the stock is currently owned by corporate insiders.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.